NLRP3 inhibitors (Idera Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNLRP3 inhibitors (Idera Pharmaceuticals)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsCystitis, InterstitialUveitisMuscular Dystrophy, Facioscapulohumeral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAceragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAceragen Inc
Active IndicationsN/A
Inactive IndicationsCystitis, InterstitialUveitisMuscular Dystrophy, Facioscapulohumeral

Other Information

ATC CodeN/A
Related LinksN/A